We first confirmed that Lrrk containing a mutation (Lrrk-R1069C) homologous to the Parkinson’s disease-promoting Roc GTPase mutation LRRK2-R1441C enhanced the toxicity of transgenic human α-synuclein. This evidence concerns the gene LRRK2 and Parkinson disease.